Target intelligence / Profile preview

Integrin beta-4 subunit (ITGB4)

Target
ITGB4
Molecular classification
Receptor, Transmembrane glycoprotein, Cell adhesion molecule, Integrin family
01

Overview

Integrin beta-4 subunit (ITGB4), also known as CD104, is a transmembrane glycoprotein that forms a receptor complex with integrin alpha-6, termed α6β4 integrin. This complex is a key mediator of cell adhesion to the extracellular matrix, especially via its interaction with laminins. ITGB4 plays a critical role in the structural organization of hemidesmosomes, anchoring epithelial cells to underlying connective tissue and stabilizing the skin. Its cytoplasmic domain is unusually large among integrins and is essential for hemidesmosome assembly and interaction with the cytoskeleton. ITGB4 is central to signaling pathways that regulate epithelial cell growth, migration, polarity, and survival. Mutation or dysregulation of ITGB4 is linked to inherited diseases such as epidermolysis bullosa with pyloric atresia and plays a significant role in invasive carcinomas, where altered activity and localization can facilitate tumor progression and metastasis.

Other names
CD104beta-4 integrinITGB4integrin beta-4integrin subunit beta-4
02

Mechanism of action

Antagonism (blockade of integrin-ligand interaction) and modulation of cell adhesion and migration (for drugs or biologics targeting integrins in cancer)

03

Biological functions

Cell-matrix adhesionCell-cell adhesionSignal transductionRegulation of gene expressionRegulation of cell growthStrengthening and stabilizing epithelial tissuesHemidesmosome assemblyKeratinocyte polarity and motility
04

Disease associations

Cancer (especially invasive carcinomas)Epidermolysis bullosa with pyloric atresiaSkin fragility disordersOther epithelial diseases
05

Safety considerations

Potential for skin fragility and mucosal injury (due to disruption of normal integrin function)Impaired wound healingUnintended effects on epithelial integrity
06

Biomarkers

ITGB4 (Immunohistochemistry in cancer for prognosis)α6β4 integrin expression in cancer and skin disorders

Beyond the preview

Go deeper on Integrin beta-4 subunit (ITGB4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin beta-4 subunit (ITGB4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call